8 mg/3 mL (2.68 mg/mL): Delivers 2 mg per injection
Chemical Information Compound Name: Tirzepatide Compound Class: Dual Incretin Receptor Agonist Primary Targets: GLP-1 Receptor, GIP Receptor Other Name: LY3298176 Research Use Only This product is supplied strictly for laboratory and scientific research purposes only
Those affected by these disorders often require a range of tests, diagnostic evaluations, and ongoing medical services
However, the timeline can vary depending on factors like adherence to the treatment plan, dietary choices, and physical activity levels
To overcome this limitation, we previously developed Homology-independent target integration (HITI), which offers a more versatile solution by leveraging the highly accessible non-homologous end joining (NHEJ) repair machinery 5
Dosing began at 0.25 mg of each active drug and escalated every four weeks until the full 2.4 mg dose was reached by week 16